Pharmaceutical research is under unprecedented pressure to deliver precision therapies faster, more safely, and with greater real-world relevance. In this fireside chat, two of the most forward-thinking leaders in healthcare innovation will explore how AI, real-world data, and strategic ecosystem design are redefining how pharma discovers, develops, and validates therapeutics.

Moderated by Sherri Douville, CEO of Medigram and Chair of the Trustworthy Technology and Innovation Consortium (TTIC), the conversation will center on three pillars essential to pharma's next leap forward:

1. Scalable Trust in Data & Infrastructure:
   How AI systems can be deployed across complex care settings with governance, auditability, and standards compliance (e.g., IEEE UL 2933, TIPPSS), ensuring pharma can rely on clinical environments for high-integrity RWE generation.
2. AI-Enabled Discovery and Trial Acceleration:
   How Chang’s work on generative AI, federated learning, and predictive models intersects with Goyal’s leadership of Mayo Clinic Platform’s de-identified data network to dramatically improve trial design, recruitment, and monitoring.
3. Building the Right Partnerships:
   From Mercy’s 10-year alliance with Mayo Clinic Platform and more, this discussion will explore how the right collaborations (across hospitals, pharma, and regulators) can overcome fragmentation and create a future-proof clinical research backbone.

This session will equip pharma executives, R&D strategists, data scientists, and regulatory leaders with a clear vision and practical frameworks for unlocking the full potential of AI in drug development. Attendees will walk away with insights they can use immediately to strengthen real-world evidence pipelines, secure required stakeholder buy-in, and align with evolving regulatory expectations.